WESTMINSTER, Colo.--(BUSINESS WIRE)--Apr. 28, 2009--
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company
focused on developing and commercializing innovative small molecule
drugs for the treatment of cancer, today announced that Company
management will provide a corporate update and review of the first
quarter 2009 results via webcast and conference call on Tuesday, May 5,
2009 at 4:30 p.m. ET.
The webcast of this call will be available from the homepage and the
investors/media section of the Company's Web site, www.allos.com.
Alternatively, callers may participate in the conference call by dialing
877-941-1465 (domestic) or 480-629-9677(international). Participants
should reference the Allos Therapeutics conference call. Webcast and
telephone replays of the conference call will be available approximately
two hours after the completion of the call through Friday, May 15, 2009.
To access the replay, callers should dial 1-800-406-7325 (domestic) or
303-590-3030 (international) and use passcode 4060691#.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on developing
and commercializing innovative small molecule drugs for the treatment of
cancer. The Company’s lead product candidate, pralatrexate, is a
targeted antifolate designed to accumulate preferentially in cancer
cells. In February 2009, the Company announced the final results from
PROPEL, the Company’s pivotal Phase 2 trial of pralatrexate in patients
with relapsed or refractory peripheral T-cell lymphoma (PTCL). The
PROPEL trial was conducted under an agreement reached with the U.S. Food
and Drug Administration under its special protocol assessment (SPA)
process. Based on the results of the PROPEL trial, the Company submitted
a New Drug Application to the U.S. Food and Drug Administration for
pralatrexate for the treatment of relapsed or refractory PTCL in March
2009. The Company is also investigating pralatrexate in patients with
non-small cell lung cancer, bladder cancer and a range of lymphoma
sub-types. The Company currently retains exclusive worldwide rights to
pralatrexate for all indications. For additional information, please
visit www.allos.com.
Safe Harbor Statement
The 2009 first quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those contained in the "Risk Factors" section
of the Company's Form 10-K for the year ended December 31, 2008 and in
the Company's other periodic reports and filings with the Securities and
Exchange Commission. Allos is providing the information contained in the
press release and conference call as of the date of the release and does
not undertake any obligation to update any forward-looking statements as
a result of new information, future events or otherwise. The Company
cautions investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call. No
forward-looking statement can be guaranteed and actual events and
results may differ materially from those projected.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 303-426-6262
mgreer@allos.com
